Admedus encouraged by smooth start to new sales model, including first major manufacturing order
Paradigm Biopharmaceuticals targets 2019-20 milestones for OA-MPS-BMEL pipeline
Imugene presents HER2 immuno-oncology vaccines success at ESMO ahead of 2020 studies
Only registered members can use this feature.
Copyright © Proactive Investors 2019.
All Rights Reserved - Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.